Realtime AI News
Anthropic says its biology lab found a CRISPR-like enzyme system
Anthropic says its Bay Area wet lab has found a previously unknown enzyme system in bacteriophage DNA with CRISPR-like abilities to cut, copy and paste DNA. CEO Dario Amodei says it was found mostly, not entirely, by Claude, while the physical experiments were run by human scientists.

Anthropic says its biology lab has already produced a discovery it considers significant: a newly identified enzyme 'system' with properties the company describes as 'reminiscent of CRISPR.' The announcement, reported by TechCrunch on September 23, comes just a week after Anthropic confirmed it operates a wet biology lab in the Bay Area where it uses its own AI models to run physical experiments.
According to Anthropic, the finding is a previously unknown enzyme system hidden in the DNA of bacteriophages, the viruses that infect and replicate inside bacteria. The company's researchers say it behaves similarly to CRISPR in that it can 'perform operations like cutting, copying, and pasting DNA.' CRISPR began as a natural bacterial immune system for fighting viruses and became a widely used gene-editing technology.
What has drawn the most attention is how the system was found. CEO Dario Amodei wrote on X that it was discovered 'mostly, though not entirely, by Claude.' By the company's account, Claude needed only 21 hours of concerted effort, searching through data with about 950 agents that burned through 210 million tokens. The lab itself was only established this spring.
Amodei also acknowledged that the work builds on others: a Stanford team previously discovered a system 'that is in some ways similar to the one Claude found,' he wrote. Anthropic concedes it will be up to the broader research community to validate how big, or how new, the discovery actually is.
TechCrunch notes that the biggest reveal may not be the discovery at all, but that the lab has not let Claude run loose. The physical experiments were done by humans. Anthropic describes the lab as looking like a typical molecular biology lab, restricted to the lower biosafety levels BSL-1 and BSL-2 and handling no pathogens that can infect humans: 'All of the lab work is performed by human scientists.'
The timing is delicate. The news lands right after several AI CEOs, Amodei included, publicly argued that models have become capable, and potentially dangerous, enough that the industry must slow down and build safety-testing procedures, and after some Anthropic employees said this month that AI carries a risk of killing us all. Amodei has said one of his greatest fears is AI-enabled bioterrorism, while also saying he believes AI will cure most diseases in five to ten years.
Anthropic is not alone in pushing AI into biology. Researchers at Stanford just published work on LLMs and CRISPR, a UCSF team used AI to design enzymes from scratch, and Google shipped AlphaFold back in 2020. Amodei has not ruled out a fully automated lab: it may eventually be possible, he said, for Claude itself to safely perform experiments by autonomously controlling lab equipment with appropriate safeguards, 'but we aren't doing that today.'
Why it matters
If the finding survives independent validation, it becomes an early example of an AI agent producing a checkable result in real science. That Anthropic still keeps humans on every wet-lab step, and credits prior work, shows the current bottleneck is not whether a model can propose a hypothesis but who owns the evidence chain and the safety boundary.
Nearby Updates
All09/24, 07:39
Meta Unveils Camera-Free AI Glasses
Meta has introduced a version of its AI glasses that drops the camera, saying the device is lighter and offers up to 12 hours of battery life. The move trades the product's most recognizable feature for a lighter build and longer wear time.
09/24, 08:46
Meta built a Tamagotchi-like wearable for its Muse AI agent
Meta has built a Tamagotchi-like wearable for Muse, its AI agent, according to TechCrunch, giving the assistant another mobile home beyond phones and apps. The device suggests agent makers are now competing on physical form and everyday presence, not just model capability.
09/24, 03:31
Enveda raises $311M to push nature-derived AI drugs into clinical trials
Enveda has raised $311 million in a round that values the AI biotech at $2 billion, according to TechCrunch. The company is currently testing drugs for skin conditions and for preserving weight loss after patients stop taking GLP-1 medications.
09/24, 09:13
Meta Goes All-In on Its AI Agent Muse at Connect
Meta opened its annual Connect event in Menlo Park with a keynote from CEO Mark Zuckerberg that put the AI agent Muse at the center. The company says Muse is coming to Meta's AI glasses as well.